Alkermes PLC (ALKS)

57.70
NASDAQ : Health Care
Prev Close 57.94
Day Low/High 57.50 / 58.61
52 Wk Low/High 39.65 / 62.50
Avg Volume 850.20K
Exchange NASDAQ
Shares Outstanding 153.19M
Market Cap 8.88B
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Alkermes Plc Reports First Quarter 2017 Financial Results

Alkermes plc (NASDAQ: ALKS) today reported financial results for the first quarter of 2017.

Alkermes' Corporate Presentation To Be Webcast At The Deutsche Bank 42nd Annual Health Care Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Deutsche Bank 42 nd Annual Health Care Conference on Wednesday, May 3, 2017 at 8:00 a.

Alkermes To Host Conference Call To Discuss First Quarter 2017 Financial Results

Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round

Jim Cramer is bullish on Nektar Therapeutics and Alkermes, as well as Verizon and Bank of America.

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.

Alkermes To Present Preclinical Data On ALKS 4230 At The American Association For Cancer Research Annual Meeting

Alkermes plc (NASDAQ: ALKS) today announced that preclinical data on the company's immuno-oncology drug candidate, ALKS 4230, an engineered fusion protein designed for selective activation of the interleukin-2 (IL-2)...

Alkermes To Present Data On Two-Month Dosing Option Of ARISTADA® At 16th International Congress On Schizophrenia Research

Alkermes plc (NASDAQ: ALKS) today announced that data for the two-month dosing option of ARISTADA ® (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia will be...

Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study Of ALKS 8700 For Treatment Of Multiple Sclerosis

Alkermes plc (NASDAQ: ALKS) today announced the initiation of a new phase 3 study of ALKS 8700, a novel, oral monomethyl fumarate (MMF) prodrug candidate in development for the treatment of relapsing forms of...

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Alkermes' Corporate Presentation To Be Webcast At The Barclays Global Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017 at 9:00 a.

Alkermes' Corporate Presentation To Be Webcast At The Cowen And Company 37th Annual Health Care Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 37 th Annual Health Care Conference on Tuesday, Mar.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALKS, CCU, CRAY, CRNT, DX, ELMD, ESSA, NLY, OMCL, XEC Downgrades: ETR, RDCM Initiations: SGLB Read on to get TheStreet Quant Ratings' detailed report:

Alkermes Plc Reports Financial Results For The Year Ended Dec. 31, 2016 And Provides Financial Expectations For 2017

Alkermes plc (NASDAQ: ALKS) today reported financial results for the twelve months ended Dec.

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2016 Financial Results

Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Jim Cramer says he's focusing on health-care companies that will break news that moves stocks.

Alkermes' Corporate Presentation To Be Webcast At The 35th Annual J.P. Morgan Healthcare Conference

Alkermes' Corporate Presentation To Be Webcast At The 35th Annual J.P. Morgan Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the 35 th Annual J.

Short Interest Makes 14% Move For ALKS

Short Interest Makes 14% Move For ALKS

The most recent short interest data has been released for the 11/15/2016 settlement date, which shows a 772,058 share increase in total short interest for Alkermes plc , to 6,307,074, an increase of 13.95% since 10/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Alkermes (ALKS) CEO Pops Says Biotech Stocks 'Recovered Quite a Bit' Post-Election

Alkermes (ALKS) CEO Pops Says Biotech Stocks 'Recovered Quite a Bit' Post-Election

Alkermes (ALKS) CEO Richard Pops said on CNBC that the price of medicine and the type of insurance patients have are both contributing to the drug pricing problem.

Alkermes' Corporate Presentation To Be Webcast At The Jefferies 2016 London Healthcare Conference

Alkermes' Corporate Presentation To Be Webcast At The Jefferies 2016 London Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2016 London Healthcare Conference on Wednesday, Nov.

ALKERMES Inspiration Grants™ Awarded To Support People Affected By Mental Health And Substance Use Disorders

ALKERMES Inspiration Grants™ Awarded To Support People Affected By Mental Health And Substance Use Disorders

Alkermes plc (NASDAQ: ALKS), a global biopharmaceutical company developing medicines for the treatment of central nervous system (CNS) diseases, today announced the company has awarded $1 million in funds to...

Alkermes Plc Reports Third Quarter 2016 Financial Results

Alkermes Plc Reports Third Quarter 2016 Financial Results

Alkermes plc (NASDAQ: ALKS) today reported financial results for the third quarter of 2016.

Alkermes' Corporate Presentation To Be Webcast At The Credit Suisse 25th Annual Healthcare Conference

Alkermes' Corporate Presentation To Be Webcast At The Credit Suisse 25th Annual Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 25 th Annual Healthcare Conference on Tuesday, Nov.

Jim Cramer's Top Takeaways: Norfolk Southern, Apple, Snap-On

Jim Cramer's Top Takeaways: Norfolk Southern, Apple, Snap-On

Jim Cramer sees the possibility of growth for Norfolk Southern and Snap-On.

Jim Cramer's 'Mad Money' Recap: Demand and Takeover Talk Lift Stocks

Jim Cramer's 'Mad Money' Recap: Demand and Takeover Talk Lift Stocks

Strong demand drives results and gains for Boeing, Akamai and others.